2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Motivación para vacunarse y prevalencia de eventos adversos tras la inmunización ante el SARS-CoV-2. Un informe breve Translated title: Motivation for getting vaccinated and prevalence of adverse events following immunization in a sample of a hospital. A brief report

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Introducción: A principios de 2021, más de 110 millones de personas se habían contagiado por SARS-CoV-2. La urgente necesidad de intervenciones seguras y eficaces para mitigar la propagación global del SARS-CoV-2 ha impulsado esfuerzos internacionales para desarrollar antivirales y vacunas. La farmacovigilancia de eventos adversos después de la vacunación es relevante; el signo o síntoma indeseable que se manifiesta en un individuo que ha recibido algún tipo de vacunación se considera un evento adverso. Objetivo: Analizar el nivel de conocimiento y motivación para vacunarse contra el SARS-CoV-2 en el personal de un hospital con la vacuna de ARNm, describir los Eventos Adversos Posterior a la Vacunación y compararlos con las últimas notificaciones publicadas por nuestra agencia nacional de medicamentos y dispositivos médicos. Método: Se trata de un estudio descriptivo, observacional y prospectivo. La muestra estuvo compuesta por 66 trabajadores del hospital que fueron vac u n a d o s c o n l a v a c u n a A R N m COVID-19. Resultados: Más del 80% de la muestra mostró eventos adversos después de la vacunación. El efecto adverso notificado con mayor frecuencia fue las reacciones en la zona de inyección. El conocimiento sobre el efecto adverso determina la motivación para vacunarse. La motivación para vacunarse está relacionada con haber tomado medicación: el personal que está más motivado para vacunarse necesita menos medicación para aliviar los síntomas y es más probable que esté dispuesto a poner nuevas dosis si es necesario. Alrededor del 26% de la muestra se mostró ansiosa, temerosa o preocupada por ser vacunada. Conclusión: Alrededor del 75% de la muestra respondió que estaban motivados para vacunarse. Los casos de estudio presentan reacciones en el lugar de la inyección, fatiga, debilidad y artralgia; los escalofríos fueron más frecuentes que la literatura y la pirexia fue menos frecuente que la literatura. Todos los efectos adversos fueron más frecuentes después de la dosis 2. El conocimiento sobre los efectos adversos determinó la motivación para vacunarse.

          Translated abstract

          Abstract Background: At the beginning of 2021, more than 110 million people had been infected with SARS-CoV-2. The urgent need for safe and effective interventions to mitigate the global spread of SARS-CoV-2 has prompted international efforts to develop antivirals and vaccines. Pharmacovigilance for adverse events after vaccination is relevant; the undesirable sign or symptom that manifests in an individual who has received some type of vaccination is considered an adverse event. Purpose: To analyse the level of knowledge and motivation for getting vaccinated against SARS-CoV-2 in a hospital staff to the administered COVID-19 mRNA vaccine, to describe the Adverse Events Following Immunization and to compare it with the last notifications published by our national agency of drugs and medical devices. Methods: This is a descriptive, observational, and prospective study. The sample was composed of 66 hospital workers who were vaccinated with COVID-19 mRNA vaccine. Results: More than 80% of the sample showed adverse events following immunisation. The most frequently AEFI reported was injection site reactions. The knowledge about the AEFI determines motivation for getting vaccinated. Motivation for getting vaccinated is related with have taken medication: staff who is more motivated to get vaccinated needed less medication to alleviate symptoms and is more likely of being willing to put new doses if necessary. About 26% of the sample revealed anxious, fearful, or worried for being vaccinated. Conclusions: About 75% of the sample answered that they were motivated for getting vaccinated. The study cases present injection site reactions, fatigue, weakness, and arthralgia; the shaking chills were more frequent than literature and pyrexia was less frequent than literature. All AEFI were more frequent after dose 2. The knowledge about the AEFI determines motivation for getting vaccinated.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials

          Background Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination. Main text A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11–1.61, P < 0.001], 1.65 (95% CI 1.31–2.07, P < 0.001), and 2.01 (95% CI 1.78–2.26, P < 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged ≤ 55 years were at significantly higher risk of AEFI than people aged ≥ 56 years, with a pooled RR of 1.25 (95% CI 1.15–1.35, P < 0.001). Conclusions The safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions. Graphic Abstract Supplementary Information The online version contains supplementary material available at 10.1186/s40249-021-00878-5.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

            Background Vaccination against coronavirus disease 2019 (COVID-19) is underway globally to prevent the infection caused by the severe acute respiratory syndrome coronavirus 2. We aimed to investigate the adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs). Methods This was a retrospective study of the AEFIs associated with the first dose of the ChAdOx1 nCoV-19 vaccine at the Kosin University Gospel Hospital from March 3 to March 22, 2021. We investigated the systemic and local adverse events during the 7 days following the vaccination using the Mobile Vaccine Adverse Events Reporting System (MVAERS) developed by our hospital. Results A total of 1,503 HCWs were vaccinated, and the data of 994 HCWs were reported in the MVAERS. The most commonly reported AEFIs were tenderness at the injection site (94.5%), fatigue (92.9%), pain at the injection site (88.0%), and malaise (83.8%). The severity of most AEFIs was mild-to-moderate, and the severity and number of AEFIs were less in the older age group. There were no serious events requiring hospitalization, and most AEFIs improved within a few days. Conclusion The AEFIs associated with the ChAdOx1 nCoV-19 vaccine were tolerable, and the use of the MVAERS was helpful in monitoring the AEFIs. The use of MVAERS will help in sharing accurate and ample information about vaccination against COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adverse Events Following mRNA SARS-CoV-2 Vaccination among U.S. Nursing Home Residents

              Background The devastating impact of the SARS-CoV-2 pandemic prompted the development and emergency use authorization of two mRNA vaccines in early 2020. Vaccine trials excluded nursing home (NH) residents, limiting adverse event data that directly apply to this population. Methods To prospectively monitor for potential adverse events associated with vaccination, we used Electronic Health Record (EHR) data from Genesis HealthCare, the largest NH provider in the United States. EHR data on vaccinations and pre-specified adverse events were updated daily and monitored for signal detection among residents of 147 facilities who received the first dose of vaccine between December 18, 2020 and January 3, 2021. For comparison, unvaccinated residents during the same time period were included from 137 facilities that started vaccinating at least 15 days after the vaccinating-facilities. Results As of Janary 3, 2021, 8,553 NH residents had received one dose of SARS-CoV-2 vaccine and by February 20, 2021, 8,371 residents had received their second dose of vaccine; 11,072 were included in the unvaccinated comparator group. No significant associations were noted for neurologic outcomes, anaphylaxis, or cardiac events. Conclusions No major safety problems were detected following the first or second dose of the vaccine to prevent COVID-19 in the study cohort from December 18, 2020 through March 7, 2021.
                Bookmark

                Author and article information

                Journal
                ene
                Ene
                Ene.
                Martín Rodríguez Álvaro (Santa Cruz de La Palma, La Palma, Spain )
                1988-348X
                2022
                : 16
                : 3
                : 1427
                Affiliations
                [1] orgnameGrupo de investigación en dependencia, gerontología y geriatría orgdiv1Departamento de Psiquiatría, Radiología, Salud Pública, Enfermería y Medicina
                [2] orgnameHospital QuirónSalud Lugo
                Article
                S1988-348X2022000300002 S1988-348X(22)01600300002
                ee10233a-28e3-4117-a9c3-e524d0a43755

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

                History
                : 01 July 2022
                : 01 August 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 9, Pages: 0
                Product

                SciELO Spain

                Categories
                Artículos

                personal hospitalario,actitudes,conocimiento,ansiedad,efectos adversos,SARS-CoV-2,COVID-19 vacunas,motivación,hospital staff,attitudes,knowledge,anxiety,adverse effects,COVID-19 vaccines,Motivation

                Comments

                Comment on this article